Amid Alberta’s worsening toxic drug crisis, the provincial government has side-stepped its duty to provide clear, actionable ...

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...